Search Results

TerSera Therapeutics announced a new sponsorship with the Carcinoid Cancer Foundation and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome.

TerSera Canada Inc. today announced that Health Canada has approved a supplemental New Drug Submission for ZOLADEX LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women.

TerSera Therapeutics LLC announced today that The National Comprehensive Cancer Network® (NCCN) Breast Cancer Panel included both goserelin 3.6 mg every 4 weeks and goserelin 10.8 mg every 12 weeks, as methods for ovarian function suppression in Version 1.2024 of the Breast Guidelines revised as of January 25, 2024.

TerSera Therapeutics LLC announced today the online publication of the TELEPRO-II study in the Journal of Cancer Management and Research.

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network® Head and Neck Cancers Panel included a category 2B recommendation for goserelin as useful, in certain circumstances, for recurrent, unresectable, or metastatic salivary gland tumors in Version 1.2024 of the Head and Neck Cancers Guidelines released on October 9, 2023.

TerSera Therapeutics LLC announced today the presentation of patient-reported clinical and productivity outcomes data from their registry trial (RELAX) in patients with carcinoid syndrome diarrhea (CSD) receiving treatment with Xermelo (telotristat ethyl).

Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.